BioCentury
ARTICLE | Financial News

Arch-backed HiberCell launches with over $60M to target dormant cancer cells

February 13, 2019 11:22 PM UTC

HiberCell Inc. (New York, N.Y.) launched on Feb. 7 with $60.8 million in series A funding from Arch Venture Partners to develop therapies that prevent cancer relapse and metastasis. HiberCell said it is the first company exclusively focused on detecting and targeting dormant cancer cells.

Cancer recurrence is driven by dormant disseminated tumor cells (DTCs) that lodge in distant organs before evidence of cancer recurrence or metastasis has become detectable. HiberCell said the cells are highly predictive of increased risk of metastasis...

BCIQ Company Profiles

HiberCell Inc.